Genmab As Stock Performance
| GMAB Stock | USD 29.81 0.66 2.26% |
Genmab AS has a performance score of 2 on a scale of 0 to 100. The company retains a Market Volatility (i.e., Beta) of 0.0265, which attests to not very significant fluctuations relative to the market. As returns on the market increase, Genmab AS's returns are expected to increase less than the market. However, during the bear market, the loss of holding Genmab AS is expected to be smaller as well. Genmab AS right now retains a risk of 2.16%. Please check out Genmab AS jensen alpha, maximum drawdown, semi variance, as well as the relationship between the sortino ratio and potential upside , to decide if Genmab AS will be following its current trending patterns.
Risk-Adjusted Performance
2 of 100
Weak | Strong |
Weak
Compared to the overall equity markets, risk-adjusted returns on investments in Genmab AS are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. Despite somewhat strong basic indicators, Genmab AS is not utilizing all of its potentials. The latest stock price disturbance, may contribute to short-term losses for the investors. ...more
| Begin Period Cash Flow | 9.9 B |
Genmab |
Genmab AS Relative Risk vs. Return Landscape
If you would invest 2,916 in Genmab AS on February 23, 2024 and sell it today you would earn a total of 65.00 from holding Genmab AS or generate 2.23% return on investment over 90 days. Genmab AS is currently generating 0.0573% in daily expected returns and assumes 2.1648% risk (volatility on return distribution) over the 90 days horizon. In different words, 19% of stocks are less volatile than Genmab, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Genmab AS Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Genmab AS's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Genmab AS, and traders can use it to determine the average amount a Genmab AS's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0265
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | GMAB | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 2.16 actual daily | 19 81% of assets are more volatile |
Expected Return
| 0.06 actual daily | 1 99% of assets have higher returns |
Risk-Adjusted Return
| 0.03 actual daily | 2 98% of assets perform better |
Based on monthly moving average Genmab AS is performing at about 2% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Genmab AS by adding it to a well-diversified portfolio.
Genmab AS Fundamentals Growth
Genmab Stock prices reflect investors' perceptions of the future prospects and financial health of Genmab AS, and Genmab AS fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Genmab Stock performance.
| Return On Equity | 0.18 | ||||
| Return On Asset | 0.11 | ||||
| Profit Margin | 0.31 % | ||||
| Operating Margin | 0.19 % | ||||
| Current Valuation | (26.68 B) | ||||
| Shares Outstanding | 645.91 M | ||||
| Price To Earning | 66.53 X | ||||
| Price To Book | 4.19 X | ||||
| Price To Sales | 1.17 X | ||||
| Revenue | 16.47 B | ||||
| EBITDA | 5.65 B | ||||
| Cash And Equivalents | 21.61 B | ||||
| Cash Per Share | 33.05 X | ||||
| Total Debt | 770 M | ||||
| Debt To Equity | 0.03 % | ||||
| Book Value Per Share | 498.87 X | ||||
| Cash Flow From Operations | 7.38 B | ||||
| Earnings Per Share | 1.21 X | ||||
| Total Asset | 35.29 B | ||||
| Retained Earnings | 19.02 B | ||||
| Current Asset | 12.65 B | ||||
| Current Liabilities | 823.51 M | ||||
About Genmab AS Performance
To evaluate Genmab AS Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Genmab AS generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Genmab Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Genmab AS market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Genmab's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.Genmab AS develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. Genmab AS was founded in 1999 and is headquartered in Copenhagen, Denmark. Genmab AS is traded on NASDAQ Exchange in the United States.Things to note about Genmab AS performance evaluation
Checking the ongoing alerts about Genmab AS for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Genmab AS help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.Evaluating Genmab AS's performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate Genmab AS's stock performance include:- Analyzing Genmab AS's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Genmab AS's stock is overvalued or undervalued compared to its peers.
- Examining Genmab AS's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Genmab AS's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Genmab AS's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Genmab AS's stock. These opinions can provide insight into Genmab AS's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Genmab AS. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. For information on how to trade Genmab Stock refer to our How to Trade Genmab Stock guide.Note that the Genmab AS information on this page should be used as a complementary analysis to other Genmab AS's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Complementary Tools for Genmab Stock analysis
When running Genmab AS's price analysis, check to measure Genmab AS's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Genmab AS is operating at the current time. Most of Genmab AS's value examination focuses on studying past and present price action to predict the probability of Genmab AS's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Genmab AS's price. Additionally, you may evaluate how the addition of Genmab AS to your portfolios can decrease your overall portfolio volatility.
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume |
Is Genmab AS's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Genmab AS. If investors know Genmab will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Genmab AS listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Genmab AS is measured differently than its book value, which is the value of Genmab that is recorded on the company's balance sheet. Investors also form their own opinion of Genmab AS's value that differs from its market value or its book value, called intrinsic value, which is Genmab AS's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Genmab AS's market value can be influenced by many factors that don't directly affect Genmab AS's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Genmab AS's value and its price as these two are different measures arrived at by different means. Investors typically determine if Genmab AS is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Genmab AS's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.